openPR Logo
Press release

Metastatic HER2-positive Breast Cancer Market Expected to Experience Major Growth by 2034, According to DelveInsight | Ambrx, Zymeworks/Jazz Pharma, Roche, Criterium, Seagen, Sichuan Baili Pharma,

10-25-2024 03:28 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Metastatic HER2-positive Breast Cancer Market Expected

The Key Metastatic HER2-positive Breast Cancer Companies in the market include - Daiichi Sankyo/AstraZeneca, Roche/Chugai, Seagen, MacroGenics, Ambrx, Zymeworks/Jazz Pharmaceuticals, Taiho Oncology, GeneQuantum Healthcare, Criterium, Inc., Seagen Inc., Sichuan Baili Pharma, BioInvent International AB, and others.
DelveInsight's "Metastatic HER2-positive Breast Cancer Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Metastatic HER2-positive Breast Cancer, historical and forecasted epidemiology as well as the Metastatic HER2-positive Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Metastatic HER2-positive Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Metastatic HER2-positive Breast Cancer Market Forecast [https://www.delveinsight.com/sample-request/metastatic-her2-positive-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Metastatic HER2-positive Breast Cancer Market Report:

*
The Metastatic HER2-positive Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In January 2024, Processa Pharmaceuticals revealed its intentions to broaden the scope of Next Generation Capecitabine (NGC-Cap) development by including its application in the treatment of advanced or metastatic breast cancer, starting with the forthcoming Phase II trial. NGC-Cap involves the concurrent administration of PCS6422 and low doses of Capecitabine. The company aims to commence the Phase II study in the third quarter of 2024.

*
Anti-HER2 therapies, including HERCEPTIN, PERJETA, KADCYLA, and ENHERTU, have transformed the treatment landscape for HER2-positive cancers, which were once linked to more aggressive disease and worse prognoses.

*
Seagen's extensive TUKYSA development strategy encompasses a Phase II trial (HER2CLIMB-04) that combines TUKYSA with ENHERTU for second-line treatment of HER2-positive breast cancer, as well as a Phase III trial (HER2CLIMB-05) assessing TUKYSA in combination with HERCEPTIN and Roche's PERJETA as a first-line maintenance therapy.

*
Estimates indicate that the total number of new HER2-positive breast cancer cases in the seven major markets reached approximately 102,000 in 2023. This figure is anticipated to rise throughout the forecast period from 2024 to 2034.

*
The highest number of HR+/HER2+ breast cancer cases was found in the United States, with approximately 32,000 cases reported.

*
Germany recorded the highest number of HER2-positive breast cancer cases among the EU4 and the UK, with approximately 11,000 cases in 2023, whereas Spain had the fewest cases.

*
In Japan, Stage II had the highest number of HER2-positive breast cancer cases, with approximately 6,000 cases reported in 2023.

*
Key Metastatic HER2-positive Breast Cancer Companies: Daiichi Sankyo/AstraZeneca, Roche/Chugai, Seagen, MacroGenics, Ambrx, Zymeworks/Jazz Pharmaceuticals, Taiho Oncology, GeneQuantum Healthcare, Criterium, Inc., Seagen Inc., Sichuan Baili Pharma, BioInvent International AB, and others

*
Key Metastatic HER2-positive Breast Cancer Therapies: ENHERTU (fam-trastuzumab deruxtecan-nxk), KADCYLA (ado-trastuzumab emtansine), HERCEPTIN HYLECTA, TUKYSA, MARGENZA, ARX788, Zanidatamab, TAS2940, GQ1001, Giredestrant, Alpelisib, Tucatinib, BL-M07D1, BI-1607, and others

*
The Metastatic HER2-positive Breast Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metastatic HER2-positive Breast Cancer pipeline products will significantly revolutionize the Metastatic HER2-positive Breast Cancer market dynamics.

Metastatic HER2-positive Breast Cancer Overview

Metastatic HER2-positive breast cancer refers to breast cancer that has spread beyond the breast and nearby lymph nodes to other parts of the body, such as the bones, liver, lungs, or brain, and is characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2) protein. HER2-positive breast cancer tends to be more aggressive than other types of breast cancer.

Get a Free sample for the Metastatic HER2-positive Breast Cancer Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/metastatic-her2-positive-breast-cancer-market [https://www.delveinsight.com/report-store/metastatic-her2-positive-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Metastatic HER2-positive Breast Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Metastatic HER2-positive Breast Cancer Epidemiology Segmentation:

The Metastatic HER2-positive Breast Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Metastatic HER2-positive Breast Cancer

*
Prevalent Cases of Metastatic HER2-positive Breast Cancer by severity

*
Gender-specific Prevalence of Metastatic HER2-positive Breast Cancer

*
Diagnosed Cases of Episodic and Chronic Metastatic HER2-positive Breast Cancer

Download the report to understand which factors are driving Metastatic HER2-positive Breast Cancer epidemiology trends @ Metastatic HER2-positive Breast Cancer Epidemiology Forecast [https://www.delveinsight.com/sample-request/metastatic-her2-positive-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Metastatic HER2-positive Breast Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic HER2-positive Breast Cancer market or expected to get launched during the study period. The analysis covers Metastatic HER2-positive Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Metastatic HER2-positive Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Metastatic HER2-positive Breast Cancer Therapies and Key Companies

*
ENHERTU (fam-trastuzumab deruxtecan-nxk): Daiichi Sankyo/AstraZeneca

*
KADCYLA (ado-trastuzumab emtansine): Roche/Chugai

*
HERCEPTIN HYLECTA: Roche

*
TUKYSA: Seagen

*
MARGENZA: MacroGenics

*
ARX788: Ambrx

*
Zanidatamab: Zymeworks/Jazz Pharmaceuticals

*
TAS2940: Taiho Oncology

*
GQ1001: GeneQuantum Healthcare

*
Giredestrant: Roche

*
Alpelisib: Criterium, Inc.

*
Tucatinib: Seagen Inc.

*
BL-M07D1: Sichuan Baili Pharma

*
BI-1607: BioInvent International AB

Discover more about therapies set to grab major Metastatic HER2-positive Breast Cancer market share @ Metastatic HER2-positive Breast Cancer Treatment Landscape [https://www.delveinsight.com/sample-request/metastatic-her2-positive-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Metastatic HER2-positive Breast Cancer Market Drivers

*
Strong uptake of Daiichi/Astra's ENHERTU in second and third-line metastatic patients, owing to the unprecedented PFS any therapy in later lines could have ever achieved.

*
Therapies for treating patients whose disease is resistant or refractory to prior HER2 treatment can potentially change the market dynamics in later-line settings.

Metastatic HER2-positive Breast Cancer Market Barriers

*
As the current landscape of HER2+ is already packed with old aged blockbuster therapies, companies such as Ambrx BioPharma are developing novel therapies, aiming to target ENHERTU treated patients

*
Despite the treatment with ADCs, around 20-30% of patients progress within 12 months, so there can be a significant market opportunity for therapies targeting these patients.

Scope of the Metastatic HER2-positive Breast Cancer Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Metastatic HER2-positive Breast Cancer Companies: Daiichi Sankyo/AstraZeneca, Roche/Chugai, Seagen, MacroGenics, Ambrx, Zymeworks/Jazz Pharmaceuticals, Taiho Oncology, GeneQuantum Healthcare, Criterium, Inc., Seagen Inc., Sichuan Baili Pharma, BioInvent International AB, and others

*
Key Metastatic HER2-positive Breast Cancer Therapies: ENHERTU (fam-trastuzumab deruxtecan-nxk), KADCYLA (ado-trastuzumab emtansine), HERCEPTIN HYLECTA, TUKYSA, MARGENZA, ARX788, Zanidatamab, TAS2940, GQ1001, Giredestrant, Alpelisib, Tucatinib, BL-M07D1, BI-1607, and others

*
Metastatic HER2-positive Breast Cancer Therapeutic Assessment: Metastatic HER2-positive Breast Cancer current marketed and Metastatic HER2-positive Breast Cancer emerging therapies

*
Metastatic HER2-positive Breast Cancer Market Dynamics: Metastatic HER2-positive Breast Cancer market drivers and Metastatic HER2-positive Breast Cancer market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Metastatic HER2-positive Breast Cancer Unmet Needs, KOL's views, Analyst's views, Metastatic HER2-positive Breast Cancer Market Access and Reimbursement

To know more about Metastatic HER2-positive Breast Cancer companies working in the treatment market, visit @ Metastatic HER2-positive Breast Cancer Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/metastatic-her2-positive-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Metastatic HER2-positive Breast Cancer Market Report Introduction

2. Executive Summary for Metastatic HER2-positive Breast Cancer

3. SWOT analysis of Metastatic HER2-positive Breast Cancer

4. Metastatic HER2-positive Breast Cancer Patient Share (%) Overview at a Glance

5. Metastatic HER2-positive Breast Cancer Market Overview at a Glance

6. Metastatic HER2-positive Breast Cancer Disease Background and Overview

7. Metastatic HER2-positive Breast Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Metastatic HER2-positive Breast Cancer

9. Metastatic HER2-positive Breast Cancer Current Treatment and Medical Practices

10. Metastatic HER2-positive Breast Cancer Unmet Needs

11. Metastatic HER2-positive Breast Cancer Emerging Therapies

12. Metastatic HER2-positive Breast Cancer Market Outlook

13. Country-Wise Metastatic HER2-positive Breast Cancer Market Analysis (2020-2034)

14. Metastatic HER2-positive Breast Cancer Market Access and Reimbursement of Therapies

15. Metastatic HER2-positive Breast Cancer Market Drivers

16. Metastatic HER2-positive Breast Cancer Market Barriers

17. Metastatic HER2-positive Breast Cancer Appendix

18. Metastatic HER2-positive Breast Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metastatic-her2positive-breast-cancer-market-expected-to-experience-major-growth-by-2034-according-to-delveinsight-ambrx-zymeworksjazz-pharma-roche-criterium-seagen-sichuan-baili-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: neva
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Metastatic HER2-positive Breast Cancer Market Expected to Experience Major Growth by 2034, According to DelveInsight | Ambrx, Zymeworks/Jazz Pharma, Roche, Criterium, Seagen, Sichuan Baili Pharma, here

News-ID: 3710305 • Views:

More Releases from ABNewswire

FoxTeeShirts Redefines Sports Fashion With Sustainable, Customized, and Creative Apparel
FoxTeeShirts Redefines Sports Fashion With Sustainable, Customized, and Creative …
Image: https://www.abnewswire.com/upload/2025/10/2563ecdfe9ef8ff15f2fb39ebe50fbb0.jpg FoxTeeShirts, the innovative apparel brand blending American sports culture with sustainable fashion, is rapidly emerging as a trusted destination for fans, athletes, and creative artists worldwide. Founded in 2022 by CEO John Oliver, FoxTeeShirts has grown into a community-driven platform known for its premium Hawaiian shirts, sports-themed designs, and customizable print-on-demand services. A Vision Rooted in Sports Culture and Creative Expression FoxTeeShirts was born from Oliver's vision to create high-quality, comfortable
Epilepsy Market Expected to Gain Momentum Through 2034, According to DelveInsight | ES Therapeutics, PhytoTech Therapeutics, UCB Biopharma, SK Life Science, UCB Biopharma
Epilepsy Market Expected to Gain Momentum Through 2034, According to DelveInsigh …
The Key Epilepsy Companies in the market include - Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals/Knopp Biosciences, and others. DelveInsight's "Epilepsy Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Epilepsy, historical and forecasted epidemiology as well as the Epilepsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom
Western Suits for Wedding: How Alberto Nardoni Defines Fall 2025 Trends
Western Suits for Wedding: How Alberto Nardoni Defines Fall 2025 Trends
Why western suits for weddings are Fall 2025's top trend. Alberto Nardoni's expert styling tips, real wedding cases, and autumn fashion insights. Image: https://www.abnewswire.com/upload/2025/10/9a1dfefd79d6edb25404a716df7a2c1a.jpg Fall Weddings and the Western Trend of 2025 Western suits for wedding [https://albertonardoni.com/collections/western-suits-for-wedding] celebrations are the defining menswear trend for Fall 2025, bringing rustic charm and timeless elegance into one seamless style statement. According to The Knot 2024 Wedding Report, fall continues to be the most popular wedding season
Affordable Homecoming Suits Collection: Blue and Grey Styles That Stand Out
Affordable Homecoming Suits Collection: Blue and Grey Styles That Stand Out
Shop the 2025 collection of affordable homecoming suits for men-featuring classic grey suits and bold blue styles. Find budget-friendly options with premium quality, perfect for prom, weddings, and every formal event. Image: https://www.abnewswire.com/upload/2025/10/cba78136278fa3daf679bf6b17c83b81.jpg Finding the perfect suit for life's most important milestones doesn't need to come with a hefty price tag. Emensuits, a trusted name in men's fashion since its founding in 2004, has unveiled its 2025 collection of affordable homecoming suits

All 5 Releases


More Releases for HER2

Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics. What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period? Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. Ready to Dive into Something Exciting? Get Your Free Exclusive Sample
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period. Global HER2 Inhibitors Market Scope and Market Size The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis. Although more drug
HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously wor …
DelveInsight's HER2 negative Breast Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the HER2 negative Breast Cancer pipeline domain. Some of the essential takeaways from the HER2 negative Breast Cancer Pipeline report: • DelveInsight's HER2 negative Breast Cancer Pipeline analysis depicts a robust space with